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Assessment of the Genetic Basis of Rosacea by
Genome-Wide Association Study
Anne Lynn S. Chang1, Inbar Raber1, Jin Xu1, Rui Li1, Robert Spitale1, Julia Chen1, Amy K. Kiefer2, Chao Tian2,
Nicholas K. Eriksson2, David A. Hinds2 and Joyce Y. Tung2
Rosacea is a common, chronic skin disease that is currently incurable. Although environmental factors inﬂuence
rosacea, the genetic basis of rosacea is not established. In this genome-wide association study, a discovery group
of 22,952 individuals (2,618 rosacea cases and 20,334 controls) was analyzed, leading to identiﬁcation of two
signiﬁcant single-nucleotide polymorphisms (SNPs) associated with rosacea, one of which replicated in a new
group of 29,481 individuals (3,205 rosacea cases and 26,262 controls). The conﬁrmed SNP, rs763035 (P= 8.0× 10− 11
discovery group; P= 0.00031 replication group), is intergenic between HLA-DRA and BTNL2. Exploratory
immunohistochemical analysis of HLA-DRA and BTNL2 expression in papulopustular rosacea lesions from six
individuals, including one with the rs763035 variant, revealed staining in the perifollicular inﬂammatory inﬁltrate
of rosacea for both proteins. In addition, three HLA alleles, all MHC class II proteins, were signiﬁcantly associated
with rosacea in the discovery group and conﬁrmed in the replication group: HLA-DRB1*03:01 (P= 1.0× 10− 8
discovery group; P= 4.4× 10− 6 replication group), HLA-DQB1*02:01 (P= 1.3× 10− 8 discovery group; P= 7.2× 10− 6
replication group), and HLA-DQA1*05:01 (P= 1.4× 10− 8 discovery group; P= 7.6× 10− 6 replication group).
Collectively, the gene variants identiﬁed in this study support the concept of a genetic component for rosacea,
and provide candidate targets for future studies to better understand and treat rosacea.
Journal of Investigative Dermatology (2015) 135, 1548–1555; doi:10.1038/jid.2015.53; published online 12 March 2015
INTRODUCTION
Many causes of rosacea have been proposed over the years.
In the lay population, rosacea has been commonly attributed
to multiple external factors such as alcohol excess or sun
exposure, which can exacerbate, but are unlikely, to cause
rosacea (reviewed by Cribier (2013). Other reported asso-
ciations have included small intestinal bacterial overgrowth
and skin surface microbes (Weinstock and Steinhoff, 2013).
The important role of antimicrobial peptides (Yamasaki et al.,
2007) and the toll-like receptors2 pathway (Yamasaki et al.,
2011) has been demonstrated in rosacea pathophysiology.
Nevertheless, the potential genetic basis of this common,
disﬁguring yet incurable condition is not known. Evidence for
a genetic component to rosacea has been hypothesized, with
a retrospective study showing that rosacea patients have a
greater than fourfold increased odds of having a family
member with rosacea (Abram et al., 2010; Steinhoff et al.,
2013), but the genes leading to this association are not
known. This current study explores genes that associate with
rosacea in a large population of individuals of European
descent by genome-wide association study.
RESULTS
A genome-wide association study was conducted in 22,952
individuals whose genomes showed 497% European ances-
try. Because of the sample size needed for this study, cases
and controls were identiﬁed by an online questionnaire in
which participants responded to a survey item on whether a
healthcare professional had ever diagnosed them with rosacea.
Participants who answered “yes” were deﬁned as “cases”
(n=2,618), and those who answered “no” (n=20,334) were
deﬁned as “controls”. With this sample size, we would have
80% power to detect an association with an odds ratio of 1.25
and minor allele frequency of 20%, with Po5×10−8 (Freidlin
et al., 2002).
Basic demographics of the case and control groups are
reported in Table 1a for the discovery group and in Table 1b
for the replication group. As this study was conducted in
individuals with European ancestry, the proportion of cases
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versus controls (11 vs. 89%) was consistent with population
data from European countries, in which the prevalence of
rosacea has been reported at up to 10% of the population
(Elewski et al., 2011).
Our study’s proportion of individuals with rosacea over the
age of 60 years is 43% in the discovery group (1,119/2,618)
and 47% in the replication group (1,508/3,207), which is
consistent with known demographics of rosacea. Rosacea
prevalence is reported to increase with age in the medical
literature with about 43% diagnosed over the age of 50 years
(Elewski et al., 2011). However, this study is not a population
cohort as individuals choose whether to participate in this
study and participants may not necessarily match a natural
population.
The genome-wide association study was conducting by
adjusting for age, sex, and the ﬁrst ﬁve principal components.
Q-Q plot of the P-values for this discovery group are shown in
Supplementary Figure 1 online.
Two single-nucleotide polymorphisms (SNPs) met the
Bonferroni threshold for signiﬁcance (Po5× 10− 8) in the dis-
covery cohort: rs763035 (P= 8.0× 10–11) and rs111314066
(P=4.9× 10–8). A Manhattan plot for these results is shown in
Figure 1. Targeted interrogation of the two signiﬁcant SNPs
from the discovery group in a replication group (n=29,481)
consisting of new cases (n= 3,205) and new controls
(n=26,262; and using a signiﬁcance threshold of Po0.05
and correction for the same covariates as the discovery group)
revealed that only rs763035 was associated with rosacea
(P=0.00031; Table 2). Regional association plot of the
conﬁrmed SNP rs763035 showed linkage disequilibrium with
increasing P-values of the SNPs adjacent to rs763035
(Figure 2). Quality statistics for index SNPs are shown in
Supplementary Table 1 online.
The conﬁrmed SNP, rs763035, is intergenic and located
12,774 bp upstream of HLA-DRA (human leukocyte antigen
(HLA) class II histocompatibility antigen, DR alpha chain) and
19,945 bp downstream of BTNL2 (butyrophilin-like 2, major
histocompatibility complex class I associated).
Immunohistochemistry using antibodies against HLA-DRA
and BTNL2 both showed staining in skin biopsies of
papulopustular rosacea lesions from the lower face of six
Table 1. Gender and age characteristics of rosacea
cases and controls (a) from the discovery group and (b)
from the replication group
Characteristic Rosacea cases Controls
(a)Discovery group, n= 22,952
n (%) 2,618 (11%) 20,334 (89%)
Female (%) 1,848 (65%) 8,655 (43%)
Age (years)
o30 3 (0.001%) 3 (0.00015%)
30–45 528 (20%) 7,190 (35%)
445–60 968 (37%) 6,554 (32%)
460 1,119 (43%) 6,587 (32%)
(b) Replication group, n= 29,481
n (%) 3,207(11%) 26,274 (89%)
Female (%) 2,305 (72%) 13,216 (50%)
Age, (years)
o30 0 (0%) 0 (0%)
30–45 527 (16%) 7,554 (29%)
445–60 1,172 (37%) 9,052 (35%)
460 1,508 (47%) 9,668 (37%)
The questionnaire was targeted to participants who had self-reported their
age as ⩾ 30 years. A small number of participants in the discovery group
may have subsequently changed their age to beo30 years. Their data was
included, as the small numbers do not signiﬁcantly alter the analysis.
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Figure 1. Manhattan plot of single-nucleotide polymorphisms in the rosacea genome-wide association study of the discovery group. Single-nucleotide
polymorphisms meeting a Bonferroni threshold of signiﬁcance at Po5× 10−8 (gray line) were rs763035 and rs111314066; however, only rs763035 was
conﬁrmed in the replication group (Table 2). Results are plotted as − log10-transformed P-values from the association test.
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individuals of European descent whose rosacea phenotype
was conﬁrmed on clinical history and physical examination
by a board-certiﬁed dermatologist experienced in the
treatment of rosacea. Out of the six individuals, one was
heterozygous at rs763035 for the rosacea-associated allele
and ﬁve did not possess this allele. As this was an exploratory
study, it was not powered to enable comparison of geno-
type at rs763035 and semiquantitative differences in
Table 2. Results of the discovery group GWAS for rosacea and replication group
(a)
P-value
OR (95% CI)
Gene context
rsSNP Chromosome Position Allele
Imputed SNP
or genotyped
SNP MAF
Discovery
group
Replication
group
763035 6 32,394,845 A/G Imputed 0.1387 8.0× 10−11
1.36 (1.24–1.50)
0.00031
1.18 (1.08–1.30)
Intergenic:
12,774 bp upstream of HLA-DRA
19,945 bp downstream of BTNL2
111314066 5 144,469,907 A/T Imputed 0.0167 4.9× 10−8
1.98 (1.57–2.50)
0.326
1.15 (0.87–1.53)
Intergenic:
666,000 bp upstream of PRELID2
612,963 bp downstream of KCTD16
(b)
P-value
OR (95% CI)
HLA allele Chromosome MAF Discovery group Replication group
DRB1*03:01 6 0.1149 1.0× 10−8
0.75 (0.68–0.83)
4.4× 10−6
0.81 (0.74–0.89)
DQB1*02:01 6 0.1140 1.3× 10−8
0.75 (0.68–0.83)
7.2× 10−6
0.82 (0.75–0.89
DQA1*05:01 6 0.1142 1.4× 10−8
0.75 (0.68–0.83)
7.6× 10−6
0.82 (0.75–0.89)
Abbreviations: CI, conﬁdence interval; GWAS, genome-wide association study; HLA, human leukocyte antigen; MAF, minor allele frequency; OR, odds ratio;
SNP, single-nucleotide polymorphism.
(a) rs76035 was signiﬁcantly associated with rosacea in both the discovery and replication groups. (b) Three HLA alleles were signiﬁcantly associated with
rosacea in the discovery and replication groups. Bold font indicate the statistically signiﬁcant results.
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Figure 2. Regional association plot for rs763035, the single-nucleotide polymorphism conﬁrmed in the replication group. The y-axis shows negative
transformed − log10 of association test P-values, and x-axis shows the adjacent region on the chromosome. Colors indicate the strength of linkage disequilibrium
with the index single-nucleotide polymorphism, and plot symbols indicate imputed (+) and genotyped (o) single-nucleotide polymorphisms. The human
leukocyte antigen association is supported by numerous genotyped and imputed variants spanning an interval of about 1.5 Mb.
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immunohistochemical staining level for either HLA-DRA or
BTNL2. Nevertheless, the presence of HLA-DRA and BTNL2
in rosacea skin suggests potential biologic relevance.
In all six rosacea skin samples, the HLA-DRA antibody
strongly stained the perifollicular inﬂammatory inﬁltrate
characteristic of rosacea, as well as epidermal Langerhans
cells and endothelial cells (example shown in Figure 3a). In
adjacent nonaffected skin from the same individuals, there
was no heavy inﬂammatory inﬁltrate, and hence much fewer
cells were stained. However, visible staining of Langerhans
cells and endothelial cells could be discerned (example
shown in Figure 3b). Endothelial cell staining is very
interesting, as a cardinal feature of rosacea is vascular dilation
and proliferation (Fowler et al., 2012). Negative controls in
which the primary antibody was omitted showed no staining.
In all six rosacea skin samples, BTNL2 antibody led to
diffuse staining of the keratinocytes, as well as perifollicular
inﬂammatory inﬁltrate and endothelial cells (example shown
in Figure 3c). In adjacent nonaffected skin from the same
individuals, there was no perifollicular inﬂammatory inﬁltrate,
and hence fewer cells were stained. This staining was visible
diffusely in the keratinocytes, in the scant lymphocytes,
Langerhans cells, and endothelial cells.
Of note, HLA-DRA is invariant at its peptide-binding site,
but differences in HLA-DRA gene expression levels or
differences outside of the peptide-binding site could still occur.
Indeed, variation in the HLA-DRA promoter region has been
associated with multiple sclerosis (International Multiple
Sclerosis Genetics Consortium, 2007). Both multiple sclerosis
and rosacea are conditions with pathologic inﬂammation.
BTNL2 is a member of the immunoglobulin gene super-
family and is associated with a number of human auto-
immune diseases including inﬂammatory bowel disease and
sarcoidosis (Valentonyte et al., 2005; Sirota et al., 2009;
Anderson et al., 2011), the latter being a granulomatous
condition involving skin. Rosacea pathology is characterized
by inﬂammation, and a subtype can display granulomas as
well (Rallis and Korﬁtis, 2012).
To explore whether rs763035 is transcribed or found near
known regulatory elements, the Encyclopedia of DNA
Elements database was searched. However, rs763035 was
not located in H3K27Ac or H3K4Me1 marks often found near
active regulatory elements in seven cell lines (University of
California Santa Cruz genome browser, accessed on 3
February 2014), nor was rs763035 in DNAseI hypersensitivity
clusters, indicating open chromatin sites in 125 cell types
from Encyclopedia of DNA Elements. Although the SNP was
not found to be within known regulatory elements, Encyclo-
pedia of DNA Elements includes only some cell types, such as
basal keratinocytes in skin. Although the basal keratinocytes
in rosacea skin did stain with BTNL2 antibody, they did not
stain with HLA-DRA antibody. Notably, cutaneous Langer-
hans cells and endothelial cells, which stained in rosacea skin
with both HLA-DRA and BTNL2 antibodies, were not
represented in the Encyclopedia of DNA Elements database.
As the genotyping platform covered a maximum of
1,008,948 SNPs and an estimated 10 million SNPs exist in
the human genome, we searched for SNPs in high linkage
disequilibrium with rs763035. Three SNPs on chromosome 6
were found to be in linkage disequilibrium with the rs763035
polymorphism using the 1000GenomesProject database:
rs1894552 (r2=0.953), rs2105903 (r2=0.953), and rs2105902
(r2=0.857). These three SNPs in linkage disequilibrium with
rs763035 were not intragenic or in regulatory regions.
Rs763035 was not reported as an expression quantitative
trait locus (eQTL) for skin in a Genotype-Tissue Expression
search of skin (http://commonfund.nih.gov/GTex/index,
accessed on 25 November 2013). However, in monocytes,
rs763035 was associated with an eQTL at a distance of
418,831 bp, associated with the gene HLA-DOB
(P=1.9× 10−19).
A gene network analysis to assess gene relationships of the
genes closest to the validated signiﬁcant SNP was performed
by GeneMANIA (accessed on 13 September 2014). HLA-DRA
and BTNL2 are connected by coexpression via HLA-DRB5
and CIITA (class II, major histocompatibility complex, trans-
activator).
Because the HLA system is highly polymorphic, has a key
role in presentation of antigen, and has been associated with
multiple human diseases, HLA allelic association was
analyzed by imputation using attribute bagging with haplo-
type inference from unphased SNPs and HLA types (HIBAG;
Zheng et al, 2013). Regression using the same set of
covariates as in the SNP-based genome-wide association
Figure 3. Genes associated with rs763035 are present in rosacea skin.
(a) Rosacea skin from an individual of European descent and heterozygous for
the minor allele at rs763035 immunostained with human leukocyte antigen-
DRA antibody with a strong signal in the perifollicular inﬂammatory inﬁltrate
(black and white arrow), epidermal Langerhans cells (single black arrow), and
endothelial cells (double arrows). (b) Rosacea skin from the same individual as
a and b immunostained with BTNL2 antibody showed mild–moderate staining
in keratinocytes, perifollicular inﬁltrate (black and white arrow), and
endothelial cells (double arrow). (c) Normal skin from the same individual
stains with human leukocyte antigen-DRA antibody but lacks perifollicular
inﬁltrate, numerous epidermal Langerhans cells, and dilated blood vessels
seen in rosacea skin. (d) Normal skin from the same individual stained with
BTNL2 antibody in keratinocytes but does not contain inﬂammatory
inﬁltrate or dilated blood vessels. Negative controls were performed for all the
tissues above by omitting either human leukocyte antigen-DRA or BTNL2
primary antibodies, and these displayed no staining (data not shown).
Scale bar= 100 μm.
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study (GWAS) for rosacea phenotype resulted in three
signiﬁcant associations: HLA-DRB1*03:01 (P=1.0×10− 8),
HLA-DQB1*02:01 (P= 1.3× 10−8), and HLA-DQA1*05:01
(P= 1.4× 10−8; Table 2). All of these associations were
conﬁrmed through the replication group described above,
using a signiﬁcance threshold of Po0.05 and were as
follows: HLA-DRB1*03:01 (P=4.4×10−6), HLA-DQB1*02:01
(P= 7.2× 10−6), and HLA-DQA1*05:01 (P=7.6× 10−6;
Table 2).
DISCUSSION
All of these HLA allele associations have links to other
autoimmune diseases. The DRB1*03:01-DQB1*02:01-
DQA1*05:01 haplotype has been associated with type I
diabetes (Erlich et al., 2008), and HLA-DRB1*03:01 is
associated with retinopathy in type I diabetics (Kastelan
et al., 2013), a vascular proliferative disorder of the eye.
Rosacea also exhibits abnormal proliferation of blood vessels
including on the ocular conjunctiva. HLA-DQB1*02:01 has
been associated with celiac disease in humans (Krini et al.,
2012), a condition that can have skin manifestations. Celiac
disease involves the small intestine, and rosacea has been
associated with conditions located in the small intestine,
namely small intestinal bacterial overgrowth (Weinstock and
Steinhoff, 2013). Together, these data strongly suggest a role
for antigen presentation by class II HLA in the etiology of
rosacea.
The data presented from this large discovery and replication
group provide evidence for a genetic component of rosacea.
The association of rosacea with HLA-DRA and other HLA
alleles is consistent with the inﬂammatory nature of the
disease. In fact, HLA-DRA, HLA-DRB, HLA-DQB, and HLA-
DQA all belong to major histocompatibility complex class II,
which presents antigen from extracellular sources, potentially
explaining the connection of various microbes with rosacea
suggested in the medical literature (Weinstock and Steinhoff,
2013).
One of the most interesting ﬁndings of this study is the
potential connection between rosacea and other human
diseases such as diabetes and celiac disease. As previously
mentioned,HLA-DRB1*03:01 is associated with diabetic retino-
pathy in a Croatian population of type I diabetics (Kastelan et al.,
2013). The connection between rosacea and diabetes merits
further study, as rosacea has been reported to associate
negatively with diabetic individuals on insulin or oral anti-
diabetic drugs in a retrospective study (Spoendlin et al., 2013).
This reduction in rosacea could be owing to treatment for
diabetes with insulin or antidiabetic drugs.
As rosacea is a highly visible disease, it may be a cutaneous
sign that cues healthcare providers to consider screening for
diabetes. Future study may even identify individuals at risk for
both rosacea and diabetes based on allele proﬁles, enabling
these individuals to avoid triggers such as sun exposure (for
rosacea), seek regular blood glucose screening (for diabetes),
and/or treat the diseases early to avoid long-term adverse
health sequelae (such as scarring or permanent disﬁgurement
in rosacea, or cardiovascular damage and neuropathy in
diabetes).
Within the study, the rosacea phenotype was based on self-
report of diagnosis by a healthcare provider. We cannot
exclude the possibility that some cases and controls are
incorrectly classiﬁed. Misclassiﬁcation would likely reduce
study power and not lead to false associations. Traditional
clinical phenotyping would not have been feasible for the
large sample size used in this study. However, the use of a
self-reported phenotype using an unvalidated instrument
remains a limitation of the work. Forthcoming studies will
use dermatologists’ assessments of rosacea phenotype to
validate the gene variants identiﬁed in this study in a targeted
manner.
Future studies will also be powered to investigate the effect
of the signiﬁcant SNP on gene expression and/or protein
levels in rosacea skin, with the goal of establishing a more
direct mechanistic link between the gene variants identiﬁed
here and the mechanisms by which these changes lead to the
rosacea phenotype. Additional study will also involve
extension to individuals of non-European descent.
These data could also be used to identify individual risk for
rosacea based on genotype, and explore differences in
response to various rosacea treatments based on genotype,
so that treatment choices could be more “personalized”.
Additional research based on the data in this study could lead
to the identiﬁcation of targets that could be tested and
harnessed to better treat this chronic and disﬁguring disease.
MATERIALS AND METHODS
Study design and population
The genome-wide association study was conducted in accordance
with the Declaration of Helsinki Principles, including approval by an
external Association for the Accreditation of Human Research
Protection Programs-accredited Institutional Review Board, E & I
Review Services. Participants in the GWAS were customers of the
genetics company 23andMe (Mountain View, CA), with the vast
majority residing in the United States who voluntarily consented to
release their aggregated genetic information in an anonymous
manner, as well as answer research questions via online question-
naires. Individual results were not relayed back to the participants.
Therefore, the risks of psychological harm or loss of conﬁdentiality
from participating in this study are extremely low. The discovery
group was accrued before the replication group. Accrual methods
and criteria for inclusion and exclusion in the study were the same for
both groups, as described above. None of the participants in the
discovery were in the replication group.
Skin samples from individuals with rosacea were obtained as part
of a gene expression study for rosacea, a protocol approved by the
Stanford Human Subjects Review panel (#22419). Written informed
consent in accord with the Declaration of Helsinki Principles was
obtained before all study procedures.
Statistical adjustment for covariates
Age, sex, and population stratiﬁcation in the cases versus controls
were adjusted for by multivariate regression in the GWAS. This was
performed by assuming an additive model for allelic effects with
logistic regression using the model: rosacea diagnosis ~ age+sex
+pc.0+pc.1+pc.2+pc.3+pc.4+genotype. The results in this study
were adjusted for a genomic control inﬂation factor of 1.032.
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Determination of rosacea phenotype
Rosacea phenotype of participants in both the discovery and
replication groups was determined using the same methods. To
identify cases for the purposes of GWAS, participants who self-
identiﬁed as age 30 years or older voluntarily answered the online
question “Have you ever been diagnosed with rosacea (sometimes
called adult acne or acne rosacea) by a medical professional?”
Answer choices consisted of “yes,” “no,” and “I’m not sure.” To
ensure that facial redness was not due to concomitant medical
condition unrelated to rosacea, individuals who answered “yes” to
the prior question were asked “Was the onset of your rosacea
associated with any of the following conditions? Please check all that
apply.” Choices included “lupus,” “pregnancy,” “rheumatoid arthri-
tis,” “scleroderma,” “other arthritis,” “other autoimmune disease,”
“I’m not sure,” and “None of the above”. Individuals who selected
one of the disease conditions were excluded from the GWAS.
Individuals who answered “No” to the ﬁrst question were assigned to
be controls. Owing to the large sample size needed for this study,
clinical examination for rosacea phenotype for both the discovery
group and the replication group was not feasible.
Methods of genotyping and quality control
For both discovery and replication groups, DNA extraction and
genotype analyses were performed on saliva samples by the National
Genetics Institute, a Clinical Laboratory Improvement Amendments–
certiﬁed clinical laboratory, and subsidiary of the Laboratory
Corporation of America.
Samples for the discovery and replication groups were genotyped
on one of two platforms. A portion of participants were genotyped on
the Illumina HumanHap550+ BeadChip platform, which included
SNPs from the standard HumanHap550 panel augmented with a
custom set of ~ 25,000 SNPs selected by 23andMe. The remaining
participants were genotyped on the Illumina Human OmniExpress+
BeadChip. This platform has a base set of 730,000 SNPs augmented
with ~ 250,000 SNPs to obtain a superset of the HumanHap550+
content, as well as a custom set of about 30,000 SNPs. To conﬁrm
that results from both platforms were concordant, several thousand
samples were processed with both arrays. SNPs with signiﬁcant rates
of discordant genotype calls were removed. Data from the two
platforms were imputed against the same reference panel, and
quality control ﬁlters were applied to the imputed data to remove
variants with batch effects.
Every sample that did not reach a 98.5% call rate for SNPs on the
platforms was reanalyzed. Individuals whose analyses repeatedly
failed were contacted by 23andMe customer service to provide
additional samples.
Participants in both the discovery and replication groups were
restricted to individuals with 497% European ancestry, as deter-
mined through an analysis of local ancestry via comparison with the
three HapMap 2 populations. A maximal set of unrelated individuals
was chosen for the analysis using a segmental identity-by-descent
estimation algorithm (Henn et al., 2013). Individuals were deﬁned as
related if they shared more than 700 cM identity-by-descent,
including regions in which the two individuals share either one
or both genomic segments identical-by-descent. This level of
relatedness (roughly 20% of the genome) corresponds approximately
to the minimal expected sharing between ﬁrst cousins in an outbred
population.
Participant genotype data were imputed against the August 2010
release of 1000Genomes reference haplotypes (Browning and Browning,
2007; Howie et al., 2012). First, Beagle (version 3.3.1) (University of
Washington, Seattle, WA) was used to phase batches of 8000–9000
individuals across chromosomal segments of no more than 10,000
genotyped SNPs, with overlaps of 200 SNPs. We excluded SNPs with
minor allele frequency o0.001, Hardy–Weinberg equilibrium
Po10−20, call rate o95%, or with large allele frequency dis-
crepancies compared with the 1000Genomes reference data. A total
of 860,590 genotyped SNPs passed these ﬁlters.
Full-phased chromosomes were assembled by matching the phase
of haplotypes across the overlapping segments. We imputed each
batch against the European subset of 1000Genomes haplotypes using
Minimac (2011-10-27) (University of Washington, Seattle, WA),
using 5 rounds and 200 states for parameter estimation.
For the nonpseudoautosomal region of the X chromosome, men
and women were phased together in segments, treating the men as
already phased. The pseudoautosomal regions were phased sepa-
rately. We assembled fully phased X chromosomes, representing
men as homozygous pseudo-diploids for the nonpseudoautosomal
region. We then imputed men and women together using Minimac as
with the autosomes.
For imputed GWAS results, SNPs with average r2o0.5 or
minimum r2o0.3 in any imputation batch, as well as SNPs that
had strong evidence of an imputation batch effect, were ﬂagged. To
detect imputation batch effects, we performed an analysis of variance
for the imputed genotype dosages versus imputation batch, and
ﬂagged SNPs with Po10− 50 for the null hypothesis that dosages
were independent of batch. A total of 7,381,496 imputed variants
passed these ﬁlters.
In choosing between genotyped versus imputed GWAS results, the
imputed result was chosen if it passed quality control or if a
genotyped result was unavailable. Genotyped results were used for
variants that either were not imputed (not in the 1000Genomes
reference panel) or the imputed result failed a quality ﬁlter.
After merging genotyped and imputed association test results,
logistic regression results that did not converge owing to complete
separation were ﬂagged. The ﬁnal merged analysis included
association results for 7,431,626 variants.
For case-control comparisons, we computed association test
results by logistic regression assuming additive allelic effects. For
tests using imputed data, we use the imputed dosages rather than
best-guess genotypes. We included covariates for age, gender, and
the top ﬁve principal components to account for residual population
structure. The association test P-value was computed using a
likelihood ratio test. Results for the X chromosome are computed
similarly, with men coded as if they were homozygous diploid for the
observed allele.
GWAS results were adjusted for genomic control to compensate
for variance inﬂation owing to residual population stratiﬁcation that
has not been effectively controlled through principal components in
the regression models. The genomic control inﬂation factor was
computed from the median P-value for results that passed the quality
control.
Gene associations, regulation, expression, and networks
A Manhattan plot was created to show the distribution of test statistics
reported as P-values on the y-axis and chromosomal position on
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the x-axis. The regional association plots were generated with
LocusZoom, using linkage disequilibrium data from the March 2012
release of 1000Genomes data (available from : www.ncbi.nlm.nih.
gov/variation/tools//1000genomes/).
The University of California Santa Cruz genome browser (http://
genome.ucsc.edu; hg19) was used to search the candidate SNPs for
gene associations and whether the SNPs were transcribed. GenePaint
(www.genepaint.org) and GeneCards were used to search gene
expression patterns in mice and humans. An association test for the
most signiﬁcant SNP and eQTLs within 500 kb was performed
(Stranger et al., 2007; Montgomery et al., 2010), with cutoff r240.5.
The analysis included data sets in lymphoblastoid tissue, liver (Schadt
et al., 2008), ﬁbroblast, B and T cell (Dimas et al., 2009), cerebellum,
frontal cortex, pons, temporal cortex (Gibbs et al., 2010), and
monocytes (Zeller et al., 2010). Genotype-Tissue Expression was
used to query eQTLs in skin. To establish open chromatin signatures
in and around the SNP sites, DNaseI hypersensitivity regions within
the University of California Santa Cruz genome browser were
searched. RegulomeDB was searched for potential transcription
factor binding sites of signiﬁcant SNPs. To query for SNPs in linkage
disequilibrium with the signiﬁcant SNPs, the NCBI short genetic
variation (SNV) database (www.ncbi.nlm.nih.gov/SNP/) and
1000GenomesProject database were used. HapMap was used to
interrogate allele frequencies in individuals of European ancestry.
GeneMANIA (http://geneMANIA.org) was used to search for gene
interactions in the signiﬁcant SNP.
HLA imputation and association
HLA allele dosages were imputed from SNP genotype data using
HIBAG (Zheng et al., 2013), an attribute bagging-based statistical
method implemented in the freely available R package, including
preﬁt classiﬁer trained from a large database of individuals with
known HLA alleles and SNP variation within the HLA region. Over
98% of the tagging SNPs used in HIBAG were genotyped and passed
quality control on the 23andMe platform. Alleles for HLA-A, B, C,
DPB1, DQA1, DQB1, and DRB1 loci were imputed at four-digit
resolution. The default settings of HIBAG were used. To test
associations between HLA allele dosages and phenotypes, logistic
regression was performed using the same set of covariates used in the
SNP-based GWAS for that phenotype. Separate association tests were
performed for each imputed allele.
Immunohistochemistry
The institutional review board-approved consent form for the GWAS did
not allow us to recontact participants in the discovery and replication
groups for rosacea skin samples. However, we obtained separate
institutional review board approval for an exploratory study of genotype
and protein expression of six individuals of self-reported European
ancestry with papulopustular rosacea diagnosed by a board-certiﬁed
dermatologist recruited through Stanford Medical Dermatology Clinic.
After written informed consent, peripheral blood from these individuals
was obtained for genotyping by Illumina Human OmniExpress+
BeadChip (San Diego, CA) with imputation for rs763035 using the
same methods as described for GWAS. In addition, rosacea-affected
skin and adjacent normal skin were procured from the lower 1/3 of the
face by 4mm skin punch biopsy device (Medichoice, Mechanicsville,
VA) under local anesthesia with xylocaine. All rosacea-affected skin
biopsies consisted of follicle-centered papules. Tissue was ﬁxed in
formalin solution and embedded in parafﬁn. Sections were stained with
hematoxylin and eosin to conﬁrm the rosacea diagnosis histologically.
Additional sections were subjected to the immunohistochemistry with
antibodies against HLA-DRA and BTNL2, to assess the protein
distribution of HLA-DRA and BTNL2. The primary antibodies used
were as follows: mouse anti-human monoclonal HLA-DRA antibody
[clone TAL1B5, LifeSpan BioSciences (Seattle,WA)] at 1:200 dilution,
and polyclonal rabbit anti-human primary BTNL2 antibody (Sigma-
Aldrich, St. Louis, MO), product name HPA039844) at 1:100 dilution.
Either horse or goat serum was used to block background; horseradish
peroxidase-conjugated secondary antibody was used to visualize signal.
Light microscopy was used to assess the immunohistochemical results.
Negative controls were subjected to the same steps as above with
omission of primary antibody, and showed no immunohistochemical
staining. Owing to the small sample size, staining differences could not
be quantiﬁed between the one individual with the rs763035 minor
allele and the six individuals without the minor allele. MicroSuite
Pathology version 5.0 software (Upper Sanon, PA) was used to capture
images. Images were arranged with Adobe Illustrator (San Jose, CA).
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